Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug combination for treating hyperglycemia complicated with atherosclerosis and application thereof

A technology for atherosclerosis and hyperglycemia, applied in the field of medicine, can solve the reported problems, achieve the effect of inhibiting atherosclerosis, reducing the area of ​​aortic root plaque, and reducing the level of fasting blood sugar

Active Publication Date: 2020-03-06
CHINA PHARM UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the drug combination comprising ginsenoside Rb1 and ginsenoside Rg1 has not been reported in the treatment of hyperglycemia and type II diabetes complicated with atherosclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug combination for treating hyperglycemia complicated with atherosclerosis and application thereof
  • Drug combination for treating hyperglycemia complicated with atherosclerosis and application thereof
  • Drug combination for treating hyperglycemia complicated with atherosclerosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Confirmation of efficacy of ginsenoside extract in treating hyperglycemia complicated with atherosclerosis

[0044] 1. Experimental materials

[0045] 1.1 Instruments and equipment

[0046] Shimadzu LC-30AD liquid chromatograph (Shimadzu, Japan), AB SCIEX Triple TOF TM 5600 mass spectrometry system (AB SCIEX, USA), AB SCIEX Triple Quad TM 5500LC / MS / MS mass spectrometry system (AB SCIEX, USA), Agilent ZOEBAX Eclipse Plus C18 column (2.1×150mm, 3.5μm) (Agilent, USA), Waters XBridge TM C18 (2.1mm×100mm, 3.5μm) (Waters, USA), Shimadzu AW120 electronic analytical balance (Shimadzu, Japan), Shimadzu AUW 120D electronic analytical balance (Shimadzu, Japan), Synergy TM2 multifunctional microplate reader (BioTek, U.S.), Milli-Q Gradient A10 ultrapure water device (Millipore, U.S.), Thermo SPD-2010 vacuum centrifugal concentration device (Thermo, U.S.), Genie Vortex-2 oscillator (Genie, U.S.), HitachiCR22G III cryogenic High-speed centrifuge (Hitachi, Japan), CFX96 Real-Tim...

Embodiment 2

[0100] Screening of active monomers of ginsenosides

[0101] 1. Experimental materials

[0102] 1.1 Instruments and equipment

[0103] Shimadzu LC-30AD liquid chromatograph (Shimadzu, Japan), AB SCIEX Triple TOF TM 5600 mass spectrometry system (AB SCIEX, USA), AB SCIEX Triple Quad TM 5500LC / MS / MS mass spectrometry system (AB SCIEX, USA), Agilent ZOEBAX Eclipse Plus C18 column (2.1×150mm, 3.5μm) (Agilent, USA), Shimadzu AW120 electronic analytical balance (Shimadzu, Japan), Shimadzu AUW 120D electronic analytical balance (Shimadzu, Japan), Synergy TM2 multifunctional microplate reader (BioTek, USA), Milli-Q Gradient A10 ultrapure water device (Millipore, USA), Thermo SPD-2010 vacuum centrifugal concentration device (Thermo, USA), Genie Vortex-2 oscillator (Genie, USA), Hitachi CR22G III low-temperature high-speed centrifuge (Hitachi, Japan), CFX96 Real-Time PCR system (Bio-Rad, USA), Bugbox Plus anaerobic workstation (Ruskinn, UK), HH-4 digital constant temperature water ...

Embodiment 3

[0147] Validation of drug combination for treating hyperglycemia complicated with atherosclerosis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug combination for treating hyperglycemia complicated with atherosclerosis and an application thereof. The invention provides the application of ginsenoside in preparationof a drug for treating hyperglycemia complicated with atherosclerosis for the first time, and proposes the application of the compound containing ginsenoside Rb1 and ginsenoside Rg1 in preparation ofthe drug for treating hyperglycemia complicated with atherosclerosis and type II diabetes complicated with atherosclerosis. The drug composition provided by the invention is composed of ginsenoside Rb1 and ginsenoside Rg1 with a mass ratio of 5:1. Experiments show that the drug combination used in treatment of hyperglycemia complicated with atherosclerosis not only can reduce blood sugar and improve insulin resistance, but also can inhibit formation of atherosclerotic plaques. Meanwhile, the drug composition can be applied with statins to exert an effect of synergistically resisting hyperglycemia complicated with atherosclerosis, and a new and effective treatment plan is provide for prevention and treatment of clinical diabetes-related diseases and cardiovascular diseases.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the application of ginsenoside in the preparation of medicine for hyperglycemia complicated with atherosclerosis and its pharmaceutical composition. Background technique [0002] Atherosclerosis (atherosclerosis, AS) is the main cause of ischemic heart disease and stroke, the latter two are ranked first and third in the world's leading cause of death [Global, regional, and national age-sexspecific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013, Lancet. 2015 Jan 10; 385(9963): 117-71.]. According to epidemiological surveys, about 2 / 3 of diabetic patients died of atherosclerotic cardiovascular disease[Excess Mortality among Persons with Type2Diabetes.N Engl J Med.2015Oct 29;373(18):1720-32.] . Clinical data show that when the fasting blood glucose level is higher than 105mg / dL, every 1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P3/10A61P5/50A61P9/10
CPCA61K31/704A61P3/10A61P5/50A61P9/10A61K2300/00
Inventor 郝海平曹丽娟王赟
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com